keyword
https://read.qxmd.com/read/38583119/changes-in-the-ultrasound-presentation-of-hepatocellular-carcinoma-a-center-s-three-decades-of-experience
#1
JOURNAL ARTICLE
Lydia Giannitrapani, Simona Amodeo, Luigi Mirarchi, Antonino Terranova, Aurelio Seidita, Chiara Mozzini, Daniela Cabibi, Giuseppe Brancatelli, Anna Licata, Maurizio Soresi
PURPOSE: Ultrasound (US) surveillance is a cornerstone for early diagnosis of HCC, anyway US presentation has undergone significant changes. With the aim of evaluating the effects of US surveillance program in the real-world clinical practice, we wanted to evaluate US presentation of HCCs over the last 30 years and the differences of HCCs presentation according to etiology. METHODS: 174 patients diagnosed between 1993 and 98 (G1), 96 between 2003 and 08 (G2), 102 between 2013 and 18 (G3), were compared...
April 7, 2024: Journal of Ultrasound
https://read.qxmd.com/read/38580885/direct-acting-antiviral-therapy-for-patients-with-chronic-hepatitis-c-infection-and-decompensated-cirrhosis
#2
REVIEW
Brian L Pearlman
Patients with chronic hepatitis C virus (HCV) infection and decompensated cirrhosis are an important population for antiviral therapy yet under-represented in clinical trials. HCV direct-acting antiviral (DAA) therapies, unlike interferon-containing regimens, can be safely utilized in decompensated patients. Per guidelines from the American Association for the Study of Liver Diseases (AASLD), therapy of choice in HCV and decompensated cirrhosis is sofosbuvir, an HCV polymerase inhibitor, combined with a replication complex inhibitor (NS5A inhibitor) with or without ribavirin...
April 5, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38563667/comparison-of-four-diagnostic-guidelines-for-hepatocellular-carcinoma-using-gadoxetic-acid-enhanced-liver-mri
#3
JOURNAL ARTICLE
Jeong Hee Yoon, Young Kon Kim, Jeong Woo Kim, Won Chang, Joon-Il Choi, Beom Jin Park, Jin-Young Choi, Seung-Seob Kim, Hee Sun Park, Eun Sun Lee, Jeong-Sik Yu, Seong Jin Park, Myung-Won You, Chang Hee Lee, Jeong Min Lee
Background Noninvasive diagnostic guidelines for hepatocellular carcinoma (HCC) vary across different global geographic areas, especially regarding criteria about gadoxetic acid-enhanced MRI. Purpose To compare the diagnostic performance of four different international HCC diagnosis guidelines and readers' judgment in diagnosing HCC using gadoxetic acid-enhanced MRI in patients at high risk for HCC. Materials and Methods This retrospective study included patients who had not undergone treatment, were at risk for HCC, and who underwent gadoxetic acid-enhanced MRI from January 2015 to June 2018 from 11 tertiary hospitals in South Korea...
April 2024: Radiology
https://read.qxmd.com/read/38551831/erratum-aasld-practice-guidance-on-acute-on-chronic-liver-failure-and-the-management-of-critically-ill-patients-with-cirrhosis
#4
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 29, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38550589/high-normal-alanine-aminotransferase-is-an-indicator-for-better-response-to-antiviral-therapy-in-chronic-hepatitis-b
#5
JOURNAL ARTICLE
Chao Cai, Wen-Xuan Shang, En-Hua Lin, Yu-Chun Jiang, Hong Chen, Ke Xu, Lu Chen, Rui-Cong Chen, Yi-Jing Cai, Ji Lin, Ting-Chen Cai, Xiu-Li Lin, Lei Zhang, Nai-Bin Yang, Hui-Fang Zhang, Ming-Qin Lu
BACKGROUND: Evidence shows people living with CHB even with a normal ALT (40U/L as threshold) suffer histological disease and there is still little research to evaluate the potential benefit of antiviral benefits in them. METHODS: We retrospectively examined 1352 patients who underwent liver biopsy from 2017 to 2021 and then obtained their 1-year follow-up data to analyze. RESULTS: ALT levels were categorized into high and low, with thresholds set at >29 for males and >15 for females through Youden's Index...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38547334/noninvasive-assessment-of-liver-fibrosis-and-portal-hypertension
#6
JOURNAL ARTICLE
Andres Duarte-Rojo, Keyur Patel, Don C Rockey
PURPOSE OF REVIEW: The result of ongoing liver injury - and disease, regardless of cause - is fibrosis, and fibrosis appears to be a critically important result of ongoing injury. Further, in a number of different liver diseases, the presence of fibrosis has prognostic value. Therefore, the assessment of fibrosis is of critical clinical importance. Given the importance of fibrosis, there has been a rapid evolution in the use of noninvasive liver tests. This review highlights a number of the core principles surrounding...
March 29, 2024: Current Opinion in Gastroenterology
https://read.qxmd.com/read/38536021/quality-measures-in-pre-liver-transplant-care-by-the-practice-metrics-committee-of-the-american-association-for-the-study-of-liver-diseases
#7
JOURNAL ARTICLE
Mayur Brahmania, Alexander Kuo, Elliot B Tapper, Michael Volk, Jennifer M Vittorio, Marwan Ghabril, Timothy Morgan, Fasiha Kanwal, Neehar D Parikh, Paul Martin, Shivang Mehta, Gerald S Winder, Gene Y Im, David Goldberg, Jennifer C Lai, Andres Duarte-Rojo, Angelo H Paredes, Arpan A Patel, Amandeep Sahota, Lisa M McElroy, Charlie Thomas, Anji E Wall, Maricar Malinis, Saima Aslam, Douglas A Simonetto, Nneka N Ufere, Sudha Ramakrishnan, Mary Margaret Flynn, Yasmin Ibrahim, Sumeet K Asrani, Marina Serper
INTRODUCTION: The LT evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures (PREMs) along the continuum of pre-LT care to reduce care variation and guide patient-centered care. METHODS: Following a systematic literature review, candidate pre-LT measures were grouped into four phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance...
March 27, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38501671/assessment-of-the-2021-aasld-practice-guidance-for-albumin-infusion-in-elective-therapeutic-paracentesis-a-regression-discontinuity-design
#8
JOURNAL ARTICLE
Tomohiro Tanaka, Mark Vander Weg, Michael P Jones, George Wehby
BACKGROUND: The 2021 American Association for the Study of Liver Disease (AASLD) Practice Guidance recommends albumin infusion when removing ≥ 5 liters of ascites to prevent post-paracentesis circulatory dysfunction. However, the optimal criteria and scenarios for initiating albumin infusion subsequent to therapeutic paracentesis (TP) have been subject to limited scientific inquiry. METHODS: We conducted a retrospective cohort study at a U.S. academic healthcare center...
March 19, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38500443/prevalence-of-at-risk-mash-metald-and-alcohol-associated-steatotic-liver-disease-in-the-general-population
#9
JOURNAL ARTICLE
Carolin V Schneider, Kai Markus Schneider, Anastasia Raptis, Helen Huang, Christian Trautwein, Rohit Loomba
BACKGROUND: The prevalence of at-risk metabolic dysfunction-associated steatohepatitis (at-risk MASH) has not been systematically assessed. AIM: To delineate the prevalence of at-risk MASH in a large population-based cohort. METHODS: We conducted a cross-sectional analysis of 40,189 patients in the UK Biobank who underwent liver MRI. Hepatic steatosis was determined by proton density fat fraction (PDFF) ≥5%. Based on AASLD criteria, participants were classified as alcohol-associated steatotic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), combined metabolic alcoholic liver disease (MetALD) and at-risk MASH...
March 19, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38489663/aasld-practice-guideline-on-non-invasive-liver-disease-assessments-of-portal-hypertension
#10
JOURNAL ARTICLE
Richard K Sterling, Sumeet K Asrani, Deborah Levine, Andres Duarte-Rojo, Keyur Patel, Maria Isabel Fiel, Daniel H Leung, Bachir Taouli, Mouaz Alsawas, M Hassan Murad, Jonathan Dranoff, Tamar H Taddei, Don C Rockey
No abstract text is available yet for this article.
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38489523/aasld-practice-guideline-on-blood-based-non-invasive-liver-disease-assessments-of-hepatic-fibrosis-and-steatosis
#11
JOURNAL ARTICLE
Richard K Sterling, Keyur Patel, Andres Duarte-Rojo, Sumeet K Asrani, Mouaz Alsawas, Jonathan Dranoff, Maria Isabel Fiel, M Hassan Murad, Daniel H Leung, Deborah Levine, Tamar H Taddei, Bachir Taouli, Don C Rockey
No abstract text is available yet for this article.
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38489521/imaging-based-non-invasive-liver-disease-assessment-for-staging-liver-fibrosis-in-chronic-liver-disease-a-systematic-review-supporting-the-aasld-practice-guideline
#12
JOURNAL ARTICLE
Andres Duarte-Rojo, Bachir Taouli, Daniel H Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Hafar, Ayca Dundar, M Hassan Murad, Don C Rockey, Mouaz Alsawas, Richard K Sterling
BACKGROUND AND AIMS: Transient elastography (TE), shear-wave elastography (SWE), and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F). APPROACH AND RESULTS: A comprehensive search for studies assessing LSM by TE, SWE, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), utilizing histopathology as standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed...
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38489518/aasld-practice-guideline-on-imaging-based-non-invasive-liver-disease-assessments-of-hepatic-fibrosis-and-steatosis
#13
JOURNAL ARTICLE
Richard K Sterling, Andres Duarte-Rojo, Keyur Patel, Sumeet K Asrani, Mouaz Alsawas, Jonathan A Dranoff, Maria Isabel Fiel, M Hassan Murad, Daniel H Leung, Deborah Levine, Tamar H Taddei, Bachir Taouli, Don C Rockey
No abstract text is available yet for this article.
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38489517/accuracy-of-blood-based-biomarkers-for-staging-liver-fibrosis-in-chronic-liver-disease-a-systematic-review-supporting-the-aasld-practice-guideline
#14
JOURNAL ARTICLE
Keyur Patel, Sumeet K Asrani, Maria Isabel Fiel, Deborah Levine, Daniel H Leung, Andres Duarte-Rojo, Jonathan A Dranoff, Tarek Nayfeh, Bashar Hasan, Tamar H Taddei, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Muayad Alzuabi, Jingyi Ding, Nigar Sofiyeva, M Hassan Murad, Mouaz Alsawas, Don C Rockey, Richard K Sterling
BACKGROUND AND AIMS: Blood-based biomarkers have been proposed as an alternative to liver biopsy for non-invasive liver disease assessment (NILDA) in chronic liver disease (CLD). Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4) and cirrhosis (F4), as compared to biopsy in CLD. APPROACH AND RESULTS: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022...
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38489516/non-invasive-liver-disease-assessment-to-identify-portal-hypertension-a-systematic-review-supporting-the-aasld-practice-guideline
#15
JOURNAL ARTICLE
Don C Rockey, Mouaz Alsawas, Andres Duarte-Rojo, Keyur Patel, Deborah Levine, Sumeet K Asrani, Bashar Hasan, Tarek Nayfeh, Yahya Alsawaf, Samer Saadi, Konstantinos Malandris, M Hassan Murad, Richard K Sterling
INTRODUCTION: Portal hypertension is a serious complication of cirrhosis, which leads to life-threatening complications. Hepatic venous pressure gradient (HVPG), a surrogate of portal pressure, is the reference standard test to assess the severity of portal hypertension. However, since HVPG is limited by its invasiveness and by its availability, non-invasive liver disease assessments (NILDAs) to assess portal pressure, especially clinically significant portal hypertension (CSPH), are needed...
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38487735/new-classification-of-drug-induced-liver-injury-dili-in-aasld-guidance-what-is-next
#16
EDITORIAL
Cemal Nuri Ercin
No abstract text is available yet for this article.
2024: Hepatol Forum
https://read.qxmd.com/read/38445559/metabolic-dysfunction-associated-steatotic-liver-disease-update-and-impact-of-new-nomenclature-on-the-american-association-for-the-study-of-liver-diseases-practice-guidance-on-nonalcoholic-fatty-liver-disease
#17
JOURNAL ARTICLE
Fasiha Kanwal, Brent A Neuschwander-Tetri, Rohit Loomba, Mary E Rinella
This commentary discusses how clinicians and various stakeholders can utilize the recently published American Association for the Study of Liver Diseases nonalcoholic fatty liver disease (AASLD NAFLD) Practice Guidance in light of the change in the nomenclature to steatotic liver disease and its subcategories. The new terminologies explained in this commentary make it easier for the readers to interchangeably use metabolic dysfunction-associated steatotic liver disease (MASLD) in place of NAFLD and metabolic-dysfunction associated steatohepatitis (MASH) instead of nonalcoholic steatohepatitis (NASH), respectively, as they read the NAFLD Practice Guidance...
November 9, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38428706/degree-of-discordance-between-fib-4-and-transient-elastography-an-application-of-current-guidelines-on-general-population-cohort
#18
JOURNAL ARTICLE
Madeleine Chang, Devon Chang, Sudha Kodali, Stephen A Harrison, Mark Ghobrial, Naim Alkhouri, Mazen Noureddin
BACKGROUND AND AIMS: In the AGA/AASLD Clinical Care Pathway, Fibrosis-4 index (FIB-4) is used to stratify patients at risk for metabolic-dysfunction-associated-steatotic liver disease (MASLD) as low-, indeterminate-, or high-risk for developing advanced liver fibrosis. We assessed the performance of FIB-4 in a general population. METHODS: Using the 2017-2020 National Health and Nutrition Examination Surveys (NHANES) dataset, we selected subjects ≥18 years who had FibroScan® data...
February 28, 2024: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/38399970/simplified-criteria-to-assess-long-term-antiviral-treatment-indication-in-chronic-hbv-infected-pregnant-women-in-cambodia
#19
JOURNAL ARTICLE
Jee-Seon Yang, Saren Sovann, Yusuke Shimakawa, Sovann Nhoueng, Bunnet Dim, Chanlina Vong, Channa Sann, Julia Guillebaud, Darapolin Vann, Bunrith Touch, Hyna Chea, Wathanak Pisey Choupoan Phirum, Eric Rosenthal, Christelle Paul, Leangchhun Khun, Chantana Yay, Denis Laurent, Samsorphea Chhun, Laurence Borand, Olivier Segeral
Pregnant women identified to carry hepatitis B surface antigen (HBsAg) should be linked to care for the determination of the need for long-term antiviral therapy (LTT). We assessed the performance of simplified criteria, free from HBV DNA quantification, to select women eligible for LTT using different international guidelines as a reference. A retrospective analysis of HBV-infected pregnant women enrolled in the phase 4 ANRS TA-PROHM study was conducted in Cambodia. Sensitivity, specificity, and AUROC were computed to compare three simplified criteria (TREAT-B, HBcrAg/ALT, and TA-PROHM) with the American (AASLD) and European (EASL) guidelines as a reference...
January 26, 2024: Viruses
https://read.qxmd.com/read/38379018/esr-essentials-diagnosis-of-hepatocellular-carcinoma-practice-recommendations-by-esgar
#20
REVIEW
Roberto Cannella, Marc Zins, Giuseppe Brancatelli
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide. Current guidelines for the noninvasive diagnosis of HCC are provided by the European Association for the Study of the Liver (EASL), the American Association for the Study of Liver Diseases (AASLD) which endorsed the Liver Imaging Reporting and Data System (LI-RADS) algorithm, the Korean Liver Cancer Association-National Cancer Center (KLCA-NCC), and the Asian-Pacific Association for the Study of the Liver (APASL)...
February 21, 2024: European Radiology
keyword
keyword
60147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.